Export 27 results:
Author Title [ Type(Desc)] Year
Filters: Author is Horowitz, Mary M  [Clear All Filters]
Journal Article
R. F. Ambinder, Wu, J., Logan, B., Durand, C. M., Shields, R., Popat, U. R., Little, R. F., McMahon, D. K., Cyktor, J., Mellors, J. W., Ayala, E., Kaplan, L. D., Noy, A., Jones, R. J., Howard, A., Forman, S. J., Porter, D., Arce-Lara, C., Shaughnessy, P., Sproat, L., Hashmi, S. K., Mendizabal, A. M., Horowitz, M. M., Navarro, W. H., and Alvarnas, J. C., Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial., Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2160-2166, 2019.
A. Krishnan, Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., Laport, G., Qazilbash, M. H., Rowley, S., Sahebi, F., Somlo, G., Vogl, D. T., Weisdorf, D., Ewell, M., Wu, J., Geller, N. L., Horowitz, M. M., Giralt, S., and Maloney, D. G., Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial., Lancet Oncol, vol. 12, no. 13, pp. 1195-203, 2011.
J. C. Alvarnas, Le Rademacher, J., Wang, Y., Little, R. F., Akpek, G., Ayala, E., Devine, S., Baiocchi, R., Lozanski, G., Kaplan, L., Noy, A., Popat, U., Hsu, J., Morris, L. E., Thompson, J., Horowitz, M. M., Mendizabal, A., Levine, A., Krishnan, A., Forman, S. J., Navarro, W. H., and Ambinder, R., Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial., Blood, vol. 128, no. 8, pp. 1050-8, 2016.
E. A. Stadtmauer, Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Knust, K., Landau, H., Brunstein, C., McCarthy, P., Nelson, C., Qazilbash, M. H., Shah, N., Vesole, D. H., Vij, R., Vogl, D. T., Giralt, S., Somlo, G., and Krishnan, A., Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial., J Clin Oncol, vol. 37, no. 7, pp. 589-597, 2019.
M. R. Tomblyn, Ewell, M., Bredeson, C., Kahl, B. S., Goodman, S. A., Horowitz, M. M., Vose, J. M., Negrin, R. S., and Laport, G. G., Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response., Biol Blood Marrow Transplant, vol. 17, no. 7, pp. 1051-7, 2011.
M. C. Pasquini, Logan, B., Jones, R. J., Alousi, A. M., Appelbaum, F. R., Bolaños-Meade, J., Flowers, M. E. D., Giralt, S., Horowitz, M. M., Jacobsohn, D., Koreth, J., Levine, J. E., Luznik, L., Maziarz, R., Mendizabal, A., Pavletic, S., Perales, M. - A., Porter, D., Reshef, R., Weisdorf, D., and Antin, J. H., Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials., Biol Blood Marrow Transplant, vol. 24, no. 6, pp. 1274-1280, 2018.
M. C. Pasquini, Devine, S., Mendizabal, A., Baden, L. R., Wingard, J. R., Lazarus, H. M., Appelbaum, F. R., Keever-Taylor, C. A., Horowitz, M. M., Carter, S., O'Reilly, R. J., and Soiffer, R. J., Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transpl, J Clin Oncol, vol. 30, no. 26, pp. 3194-201, 2012.
S. J. Lee, Logan, B., Westervelt, P., Cutler, C., Woolfrey, A., Khan, S. P., Waller, E. K., Maziarz, R. T., Wu, J., Shaw, B. E., Confer, D., Horowitz, M. M., and Anasetti, C., Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial., JAMA Oncol, vol. 2, no. 12, pp. 1583-1589, 2016.
R. Spellecy, Tarima, S., Denzen, E., Moore, H., Abhyankar, S., Dawson, P., Foley, A., Gersten, I., Horwitz, M., Idossa, L., Joffe, S., Kamani, N., King, R., Lazaryan, A., Morris, L., Horowitz, M. M., and Majhail, N. S., Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study., Biol Blood Marrow Transplant, vol. 24, no. 10, pp. 2145-2151, 2018.
E. M. Denzen, Santibáñez, M. E. Burton, Moore, H., Foley, A., Gersten, I. D., Gurgol, C., Majhail, N. S., Spellecy, R., Horowitz, M. M., and Murphy, E. A., Easy-to-read informed consent forms for hematopoietic cell transplantation clinical trials., Biol Blood Marrow Transplant, vol. 18, no. 2, pp. 183-9, 2012.
A. M. Alousi, Weisdorf, D. J., Logan, B. R., Bolaños-Meade, J., Carter, S., DiFronzo, N., Pasquini, M., Goldstein, S. C., Ho, V. T., Hayes-Lattin, B., Wingard, J. R., Horowitz, M. M., and Levine, J. E., Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network., Blood, vol. 114, no. 3, pp. 511-7, 2009.
P. B. Jacobsen, Le-Rademacher, J., Jim, H., Syrjala, K., Wingard, J. R., Logan, B., Wu, J., Majhail, N. S., Wood, W., J Rizzo, D., Geller, N. L., Kitko, C., Faber, E., Abidi, M. H., Slater, S., Horowitz, M. M., and Lee, S. J., Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902., Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1530-6, 2014.
J. Tolar, H Deeg, J., Arai, S., Horwitz, M., Antin, J. H., McCarty, J. M., Adams, R. H., Ewell, M., Leifer, E. S., Gersten, I. D., Carter, S. L., Horowitz, M. M., Nakamura, R., Pulsipher, M. A., Difronzo, N. L., Confer, D. L., Eapen, M., and Anderlini, P., Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels., Biol Blood Marrow Transplant, vol. 18, no. 7, pp. 1007-11, 2012.
J. - A. H. Young, Logan, B. R., Wu, J., Wingard, J. R., Weisdorf, D. J., Mudrick, C., Knust, K., Horowitz, M. M., Confer, D. L., Dubberke, E. R., Pergam, S. A., Marty, F. M., Strasfeld, L. M., Brown, J. Wes M., Langston, A. A., Schuster, M. G., Kaul, D. R., Martin, S. I., and Anasetti, C., Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors., Biol Blood Marrow Transplant, vol. 22, no. 2, pp. 359-370, 2016.
W. Saber, Le Rademacher, J., Sekeres, M., Logan, B., Lewis, M., Mendizabal, A., Leifer, E., Appelbaum, F. R., Horowitz, M. M., Nakamura, R., and Cutler, C. S., Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and M, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1566-72, 2014.
B. L. Scott, Pasquini, M. C., Logan, B. R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E. D., Fernandez, H. F., Alyea, E. P., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Le-Rademacher, J., Mendizabal, A. M., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes., J Clin Oncol, vol. 35, no. 11, pp. 1154-1161, 2017.
J. E. Wagner, Eapen, M., Carter, S., Wang, Y., Schultz, K. R., Wall, D. A., Bunin, N., Delaney, C., Haut, P., Margolis, D., Peres, E., Verneris, M. R., Walters, M., Horowitz, M. M., and Kurtzberg, J., One-unit versus two-unit cord-blood transplantation for hematologic cancers., N Engl J Med, vol. 371, no. 18, pp. 1685-94, 2014.
C. Anasetti, Logan, B. R., Lee, S. J., Waller, E. K., Weisdorf, D. J., Wingard, J. R., Cutler, C. S., Westervelt, P., Woolfrey, A., Couban, S., Ehninger, G., Johnston, L., Maziarz, R. T., Pulsipher, M. A., Porter, D. L., Mineishi, S., McCarty, J. M., Khan, S. P., Anderlini, P., Bensinger, W. I., Leitman, S. F., Rowley, S. D., Bredeson, C., Carter, S. L., Horowitz, M. M., and Confer, D. L., Peripheral-blood stem cells versus bone marrow from unrelated donors., N Engl J Med, vol. 367, no. 16, pp. 1487-96, 2012.
J. Bolaños-Meade, Logan, B. R., Alousi, A. M., Antin, J. H., Barowski, K., Carter, S. L., Goldstein, S. C., Hexner, E. O., Horowitz, M. M., Lee, S. J., Levine, J. E., MacMillan, M. L., Martin, P. J., Mendizabal, A. M., Nakamura, R., Pasquini, M. C., Weisdorf, D. J., Westervelt, P., and Ho, V. T., Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802., Blood, vol. 124, no. 22, pp. 3221-7; quiz 3335, 2014.
P. A. Carpenter, Logan, B. R., Lee, S. J., Weisdorf, D. J., Johnston, L., Costa, L. J., Kitko, C. L., Bolaños-Meade, J., Sarantopoulos, S., Alousi, A. M., Abhyankar, S., Waller, E. K., Mendizabal, A., Zhu, J., O'Brien, K. A., Lazaryan, A., Wu, J., Nemecek, E. R., Pavletic, S. Z., Cutler, C. S., Horowitz, M. M., and Arora, M., A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft--host disease: BMT CTN 0801., Haematologica, vol. 103, no. 11, pp. 1915-1924, 2018.
G. A. Yanik, Horowitz, M. M., Weisdorf, D. J., Logan, B. R., Ho, V. T., Soiffer, R. J., Carter, S. L., Wu, J., Wingard, J. R., Difronzo, N. L., Ferrara, J. L., Giralt, S., Madtes, D. K., Drexler, R., White, E. S., and Cooke, K. R., Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials ne, Biol Blood Marrow Transplant, vol. 20, no. 6, pp. 858-64, 2014.
J. Pidala, Hamadani, M., Dawson, P., Martens, M., Alousi, A. M., Jagasia, M., Efebera, Y. A., Chhabra, S., Pusic, I., Holtan, S. G., Ferrara, J. L. M., Levine, J. E., Mielcarek, M., Anasetti, C., Antin, J. H., Bolaños-Meade, J., Howard, A., Logan, B. R., Leifer, E. S., Pritchard, T. S., Horowitz, M. M., and MacMillan, M. L., Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial., Blood, vol. 135, no. 2, pp. 97-107, 2020.
A. C Howard, Fernandez-Vina, M. A., Appelbaum, F. R., Confer, D. L., Devine, S. M., Horowitz, M. M., Mendizabal, A., Laport, G. G., Pasquini, M. C., and Spellman, S. R., Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)., Biol Blood Marrow Transplant, vol. 21, no. 1, pp. 4-7, 2015.
C. Cutler, Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., Hogan, W. J., Pasquini, M., MacMillan, M. L., Hsu, J. W., Waller, E. K., Grupp, S., McCarthy, P., Wu, J., Hu, Z. - H., Carter, S. L., Horowitz, M. M., and Antin, J. H., Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT., Blood, vol. 124, no. 8, pp. 1372-7, 2014.
J. Bolaños-Meade, Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Bin Chen, Y. -, Damon, L. E., Efebera, Y. A., Geller, N. L., Giralt, S. A., Hari, P., Holtan, S. G., Horowitz, M. M., Jacobsohn, D. A., Jones, R. J., Liesveld, J. L., Logan, B. R., MacMillan, M. L., Mielcarek, M., Noel, P., Pidala, J., Porter, D. L., Pusic, I., Sobecks, R., Solomon, S. R., Weisdorf, D. J., Wu, J., Pasquini, M. C., and Koreth, J., Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with, Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.